janssen science wordmark

(ciltacabtagene autoleucel)


The goal of the CARVYKTI® REMS is to mitigate the risks of cytokine release syndrome (CRS) and neurological toxicities by:

  • Ensuring that Hospitals and their Associated Clinics that dispense CARVYKTI® are specially certified and have on-site, immediate access to tocilizumab.
  • Ensuring those who prescribe, dispense, or administer CARVYKTI® are aware of how to manage the risks of CRS and neurological toxicities.

Access comprehensive information on Risk Evaluation and Mitigation Strategies for CARVYKTI®https://carvyktirems.com